|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues.
|
11344205 |
2001 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on our recent finding of anti-estrogen/ER-beta-mediated growth inhibition of prostate cancer cells in vitro, the presence of ER-beta in metastatic cells may have important implications for the treatment of late-stage disease.
|
11438457 |
2001 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggest that differential expressions of wtERbeta and ERbetacx may be prognostic predictors for prostatic cancer.
|
11726203 |
2001 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using a new monoclonal antibody, the current study reports on the differential expression of the ERbeta in tissue sections from 132 patients with prostate cancer.
|
12497580 |
2003 |
|
Malignant neoplasm of prostate
|
0.400 |
Therapeutic
|
disease |
CTD_human |
The evolving role of estrogen therapy in prostate cancer.
|
15046698 |
2002 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
The evolving role of estrogen therapy in prostate cancer.
|
15046698 |
2002 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The androgen-sensitive human prostate cancer cell line LNCaP expresses the estrogen receptor beta and androgen receptor and can be stimulated by androgens to secrete prostate-specific antigen (PSA).
|
15124082 |
2004 |
|
Malignant neoplasm of prostate
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis.
|
15161636 |
2004 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we provide new insights into the role of ERbeta in the context of an androgen-responsive prostate cancer cell line such as LNCaP, which was used as a model system together with steroid receptor negative HeLa cells.
|
15171712 |
2004 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, the data showed that (a) circulating testosterone may act with estrogenic effects downstream in the catabolic process present in the prostate, and (b) that the estrogenic effect of testosterone derivatives (ERbeta-dependent) results in the inhibition of cell migration, although it is apparently different from that linked to estradiol on the same receptor and may be protective against prostate cancer invasion and metastasis.
|
15958594 |
2005 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
[Implications of estrogens and their receptors for the development and progression of prostate cancer].
|
16220300 |
2005 |
|
Malignant neoplasm of prostate
|
0.400 |
Therapeutic
|
disease |
CTD_human |
[Implications of estrogens and their receptors for the development and progression of prostate cancer].
|
16220300 |
2005 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined whether sequence variants in the ERbeta gene are associated with prostate cancer risk.
|
16551880 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
Interactions between phytoestrogen intake and estrogen receptor-beta SNPs on prostate cancer risk were evaluated considering both multiplicative and additive effect scales.
|
16921512 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interactions between phytoestrogen intake and estrogen receptor-beta SNPs on prostate cancer risk were evaluated considering both multiplicative and additive effect scales.
|
16921512 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Interactions between phytoestrogen intake and estrogen receptor-beta SNPs on prostate cancer risk were evaluated considering both multiplicative and additive effect scales.
|
16921512 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
Apigenin suppresses cancer cell growth through ERbeta.
|
17132221 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Apigenin suppresses cancer cell growth through ERbeta.
|
17132221 |
2006 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer.
|
17585029 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
CTD_human |
Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.
|
17639508 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.
|
17639508 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERalpha and ERbeta may play important roles in the development of prostate cancer.
|
17908481 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ERbeta levels were diminished in prostate cancer and loss of ERbeta was associated with proliferation.
|
17913855 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The four tag SNPs in ESR2 were not significantly associated with prostate cancer risk, individually.
|
17932344 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The National Cancer Institute Breast and Prostate Cancer Cohort Consortium has systematically selected haplotype tagging SNPs in genes along the steroid hormone synthesis, metabolism and binding pathways, including the estrogen receptor beta (ESR2) gene.
|
17935138 |
2008 |